Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The SWITCH-SWEDEHEART trial of 17,000+ ACS patients found that a prasugrel-first policy didn't significantly outperform ticagrelor in preventing major cardiovascular events. The one bright spot: prasugrel was linked to modestly fewer major bleeding events. Experts say either drug remains a defensible default in routine care.
Nearly two decades after prasugrel and ticagrelor each proved superior to clopidogrel for acute coronary syndrome (ACS), a definitive winner between the two still hasn't emerged. The SWITCH-SWEDEHEART trial — a large, real-world, stepped-wedge cluster-randomized study involving 17,095 ACS patients across seven Swedish regions — compared a prasugrel-first policy against a ticagrelor-first policy. Results were presented at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
After one year, rates of death, heart attack, or stroke were nearly identical: 11.1% in the prasugrel group vs. 11.8% in the ticagrelor group — a non-significant difference. Prasugrel did edge out ticagrelor on one metric: major bleeding (4.2% vs. 4.4%), a statistically significant but modest reduction. Notably, the trial enrolled an older, unselected population (mean age 70; 37% were 75+), and adherence to assigned drugs was imperfect — only 61% in the prasugrel arm actually received prasugrel vs. 76% in the ticagrelor arm, with most non-adherent patients receiving clopidogrel instead.
A concurrent meta-analysis in JAMA Cardiology (15 trials, ~49,000 patients) offered a somewhat stronger endorsement of prasugrel, finding it associated with lower MACE, MI, and stent thrombosis vs. both clopidogrel and ticagrelor, with no increase in major bleeding.
Key Takeaways:
Why it matters: For clinicians managing ACS, this trial reinforces that the prasugrel-vs.-ticagrelor choice remains a clinical judgment call — not a clear-cut guideline mandate. The real-world, all-comers design of SWITCH-SWEDEHEART adds valuable nuance, but the long-running debate between these two agents is far from settled.
